Kodu・Aktsiate loetelu・Codexis Inc

Codexis Inc

Suletud

SektorTervishoid

1.47 -25.38

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

1.46

Max

1.55

Põhinäitajad
By Trading Economics
Sissetulek	-18M -8.7M
Müük	-24M 15M
Aktsiakasum	-0.1
Kasumimarginaal	-57.083
Töötajad	146
EBITDA	-23M -6.4M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+395.27% upside

Dividendid
By Acuity
Järgmine tulemuste avaldamine	12. aug 2026

Turustatistika
By TradingEconomics
Turukapital	-27M 201M
Eelmine avamishind	26.85
Eelmine sulgemishind	1.47

Uudiste sentiment

By Acuity

30%

70%

76 / 340 Pingereas Healthcare

Codexis Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

24. juuli 2026, 19:01 UTC

News

Codexis Inc shares are lower following a public offering of 16.67 million shares at $1.50 each, below Thursday's close of $1.99.

23. juuli 2026, 23:51 UTC

News

Codexis Inc announced a public offering of common stock, contributing to a notable decline in shares during after-market trading.

22. juuli 2026, 20:01 UTC

Codexis Inc shares are lower during Wednesday's session, continuing a trend of declines since Tuesday's close. The stock remains below its 20-day moving average.

Võrdlus sarnastega

Hinnamuutus

Codexis Inc Prognoos

Hinnasiht

By TipRanks

395.27% tõus

12 kuu keskmine prognoos

Keskmine 7.33 USD 395.27%

Kõrge 11 USD

Madal 2 USD

Põhineb 4 Wall Streeti analüütiku instrumendi Codexis Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

4 ratings

Osta

Hoia

Müü

Põhineb 4 analüütiku instrumendi Codexis Inc aktsia reitingul - viimase 3 kuu andmed.

Sentiment

By Acuity

76 / 340 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Codexis Inc

Codexis, Inc. discovers, develops, and sells enzymes and other proteins. The company offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, the company is currently developing its proprietary ECO Synthesis(tm) manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. It has a collaboration agreement with Nestlé Health Science to develop CDX-7108 for the treatment of exocrine pancreatic insufficiency. The company sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.